NCI Alliance for Nanotechnology in Cancer Launch Day
On September 13, 2004 the National Cancer Institute (NCI) launched the NCI Alliance for Nanotechnology in Cancer an integrated $144.3 million, five-year initiative to develop and apply nanotechnology to cancer prevention, detection, diagnosis and treatment. The Alliance will encompass researchers, clinicians, and public and private organizations that have joined forces to translate cancer-related nanotechnology research into clinical practice.
Nanotechnology has already demonstrated promising results in cancer research and treatment. This initiative builds on the scientific advances in genomics and proteomics and our understanding of the molecular underpinnings of cancer by facilitating cross-disciplinary and cross-sector collaboration with nanotechnology, which is ripe for biomedical application.
September 13, 2004
|Science Writers Media Briefing||Scientific Roundtable|
During the webcast, speakers address nanotechnology and its application to cancer, safety and ethical issues, and the future of nanotechnology and cancer. At the Scientific Roundtable, there is detailed discussion of ways in which researchers can be involved in efforts, including program funding for the creation of Centers of Cancer Nanotechnology Excellence, Multidisciplinary Research Teams, and Nanotechnology Platforms for Cancer.
DISTINGUISHED SPEAKERS INCLUDE:
- Dr. Anna Barker, Deputy Director for Advance Technologies and Strategic Partnerships, NCI
- The Honorable Phillip Bond, Under Secretary of Commerce for Technology
- Dr. Vicki Colvin, Director of the Center for Biological and Environmental Nanotechnology and Associate Professor of Chemistry, Rice University
- Dr. Gregory Downing, Director, Office of Technology and Industrial Relations, NCI
- Dr. Mauro Ferrari, Special Expert to the NCI on Nanotechnology and Professor of Biomedical Engineering, Ohio State University
- Dr. Richard Smalley, Professor of Chemistry, Physics, Astronomy, and Nanotechnology, Rice University
- Dr. Andrew von Eschenbach, Director, NCI
- Dr. Samuel Wickline, Professor of Medicine, Physics and Biomedical Engineering, Washington University
- Dr. Janet Woodcock, Acting Deputy Commissioner for Operations, U.S. Food and Drug Administration